AIDA: Allergy Immunotherapy based on Designed Allergens

Allergy is a severe immune reaction to foreign substances known as allergens, with respiratory and food allergies affecting 30% and 10% of the global population, respectively. A high structural similarity exists between pollen and food allergens. Therefore, many people suffer from both types of allergies.

Untreated allergies have detrimental effects on health-related quality of life, family economics, and work attendance.

Allergy is treated as a chronic disease, with a focus on reducing symptoms (e.g., antihistamines), which is cumbersome and expensive.

The only existing curative treatment, allergen immunotherapy (AIT), consists of up to 5-years of monthly exposure to low amounts of the triggering allergen until the immune system is desensitized.

Unfortunately, this approach is costly for healthcare providers and its efficacy varies, being especially low for patients allergic to multiple pollen and foodstuff sources.

Only 40% of patients choose to undergo AIT, and 20% of these terminate the treatment early due to strong side effects or lack of efficacy.

We propose the development of an urgently needed AIT by treating several allergies at once, achieving tolerance faster, and reducing side effects.